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Viruses that cause acute respiratory illness in the
general population and are responsible for hospitaliza-
tions in persons of all ages with underlying medical
conditions are also a common cause of respiratory dis-
ease in transplant recipients. With the widespread
availability of sensitive and reliable molecular detec-
tion methods, common respiratory viruses including
respiratory syncytial virus (RSV), influenza and parain-
fluenza viruses (PIVs), adenoviruses, rhinoviruses
(RhV), and coronaviruses have been detected world-
wide in transplant recipients. More recently, newly
identified viruses such as human metapneumoviruses
(HMPV) [1,2], new strains of coronaviruses [3], and
bocavirus have also been detected in symptomatic
transplant recipients [4].
Community-acquired respiratory viruses (CRV)
have a significant impact on the morbidity and mortal-
ity of the transplant recipient, causing a variety of dis-
eases ranging from self-limited upper respiratory tract
illnesses (URIs) to life-threatening lower respiratory
tract infection (LRTI) and occasionally disseminated
disease. Disease manifestations are dependent on the
specific virus, the type of transplant, and the type, de-
gree, and duration of immune deficiency. Pneumonia
following infection with these viruses may be primarily
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also have higher associated rates of copathogens.
Nosocomial transmission of CRVs is common,
and widespread hospital outbreaks of CRVs have oc-
curred with sometimes devastating sequelae [5,6].
Because these viruses are so easily transmitted from
person to person in both inpatient and outpatient
settings, infection control measures and enforcement
of these measures are critical in controlling the
spread of these infections [5-7]. Community
outbreaks of RSV infections typically occur during
the late fall, winter, and early spring, frequently
followed by outbreaks of human metapneumovirus.
Influenza outbreaks typically occur during the winter
in temperate climates, but may occur throughout the
year in more tropical areas. Parainfluenza virus
infections occur throughout the year, with outbreaks
occurring primarily in the spring, summer, and fall.
Other viruses, such as rhinoviruses, coronaviruses,
and adenoviruses, tend to take place throughout
the year, although sporadic outbreaks of all these
respiratory viruses may occur.
Prompt and accurate identification of the respira-
tory viral pathogen is critically important in the trans-
plant recipient because it enables specific infection
control precautions to be instituted, the initiation of
specific antiviral therapy, and the potential delay of
immunosuppressive therapy or transplantation. The
appropriate collection of specimens is critically impor-
tant for the successful identification of viruses in clin-
ical samples. Different diagnostic methods have been
used, but during recent years, the use of multiplex
PCR techniques has gained popularity because this
method may detect multiple respiratory viruses from
a single, readily obtained specimen [8,9].
Management of CRV infections has been contro-
versial. With the exception of influenza infections for
which neuramidase inhibitors have been shown to be
effective, there are no established treatments. Several
uncontrolled studies have been performed with ribavi-
rin, suggesting some efficacy at least in preventing
progression to lower tract disease [10]. Although there
is no licensed or proven therapy for parainfluenza virus
infections, ribavirin has antiviral effects against parain-
fluenza virus in cell culture and has been used for
the treatment of lower respiratory tract disease in
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documented decreased viral load and clinical improve-
ment in several children with severe combined
immunodeficiency and parainfluenza virus infection
following multiple treatments with aerosolized ribavi-
rin [12,13]. There is no laboratory data supporting
antiviral activity of oseltamivir against parainfluenza
viruses, although new parainfluenza-specific antiviral
agents with activity against the neuraminidase of para-
influenza virsues are under development. Preliminary
data indicates that infections from human bocavirus,
human coronavirus, and other newly identified viruses
such as WU/KI viruses are less likely to cause severe
problems in transplant patients compared with the
well-described viral pathogens above.T Cell Therapy for Adenovirus Infections
Adenoviruses (ADV) are nonenveloped lytic DNA
viruses. Fifty-two different human serotypes have been
identified divided into 7 subgroups or species. In
immunocompromised patients, ADV can cause lethal
disease, with damage occurring in many different
organs. During the last decade ADV infection in the
context of allogeneic hematopoietic stem cell trans-
plantation (HSCT) has been increasingly recognized
as a cause of transplant-related mortality (TRM),
especially in children and the most severely immuno-
compromised adults, such as those undergoing haploi-
dentical or T cell-depleted transplants.
Runde et al. reported a significantly higher inci-
dence of ADV-infection in patients receiving antithy-
mocyte globulin (ATG), and a study by van Tol et al.
[14] found the risks of ADV infection and disease
were increased in patients with more intensive T cell
depletion. They also demonstrated that patients with
delayed T cell recovery have a significantly higher
risk of ADV infection and disease. Other studies found
a strong correlation between the presence of ADV-
specific T cells and the clearance of ADV infection.
Feuchtinger et al. showed that patients with ADV-
specific T cells could be found in higher numbers in
patients who cleared ADV infection compared to those
who did not. Myers et al. found that a delayed recovery
of ADV-specific T cells in recipients of unrelated or
haploidentical grafts correlated with an increased risk
for ADV disease. The observation that the outcome
of ADV disease is related to specific immune reconsti-
tution suggests that the recovery of ADV-specific im-
munity is a critical process that can be improved by
decreasing the intensity of immunosuppression. In ad-
dition, the transfer of virus-specific T cells has been
shown to be effective in controlling cytomegalovirus
(CMV) and Epstein-Barr Virus (EBV) infections in
HSCT recipients. Although the different ADV sub-
types are to some extent antigenically distinct, these
same subtypes share T cell epitopes on the hexonprotein. Furthermore, crossreactivity has been shown
ex vivo. Early in vitro experiments showed that
ADV-specific T cells can be generated by ADV pulsed
dendritic cells, and that these can lyse adenoinfected
cells. Chatziandreou et al. [15] and Feuchtinger et al.
[16] isolated ADV-specific T cells through an inter-
feron (INF)-g-secretion and capture assay and could
show specific antigen responses of both CD41 and
CD81 T cells upon restimulation with different
ADV strains. Another promising approach is the adop-
tive immunotherapy with allodepleted donor T cells to
improve immune reconstitution concerning all com-
mon viruses.
In a pilot study, Feuchtinger et al. [17] treated
6 patients with ADV-viremia with virus-specific donor
T cells generated by INF-g secretion assays. In 3 of 4
evaluable patients receiving this adoptive T cell trans-
fer, the infused T cells underwent an in vivo expansion
and the viral load decreased in peripheral blood.
In vivo expansion of specific T cells was dose-
independent, suggesting that even very low numbers
of ADV-specific donor T cells expand easily in vivo
in the presence of viremia.
Vaccination of Stem Cell Transplant Recipients
Against Viral Pathogens
Influenza
Themortality rate following influenza infections in
HSCT recipients was previously reported to be around
15% [18,19], although recent data reporting outcome
after more widespread utilization of neuramidase
inhibitors suggest a somewhat lower risk for fatal
outcome [20,21]. The recent outbreak of new
pandemic strain A/H1N1 stressed the importance of
having strategies in place for management of these
patients.
Influenza infection is controlled by different parts
of the immune system including both the innate and
adaptive immune systems. After vaccination, both
T cell and B cell responses are activated. Clearance
of the primary infection depends on CD8 cells. These
cells recognize epitopes from both the hemagglutinin
(HA) and internal proteins of the influenza virus.
Following recovery from influenza, antigen-specific
T cells maintain long-lasting immunologic memory
that responds quickly to restimulation. The B cells
produce antibodies to the influenza proteins and
HA-specific antibodies appear within 2 weeks of the
infection. In contrast to antibodies directed to HA,
antibodies directed to NA do not neutralize virus but
reduces the release of virus from infected cells. A prob-
lem specific for influenza viruses is the antigenic shifts
and drifts of circulating influenza virus that regularly
occur, requiring adaptation of the seasonal tri-valent
influenza vaccines that must be administered to
provide protection.
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vated, and live, cold-adapted vaccine for intranasal ad-
ministration. Safety and efficacy of the intranasal, live
vaccine has not been evaluated in HSCT recipients
but is safe in HIV-infected adults and children. Be-
cause influenza infection occurring early after HSCT
might result in severe disease, it would be logical to im-
munize candidates before HSCT. However, most
studies show that adult patients with hematologic ma-
lignancies respond poorly to vaccination. In addition,
the likelihood that whatever immunity that does exist
will be lost is very high.
The time after HSCT is important for vaccine
responses. Engelhard et al. [22] studied the antibody
response to 2 doses of influenza virus vaccine given
2 to 82 months after HSCT to allogeneic BMT
recipients (adults and children) who had received a T
cell-depleted transplant, and showed a significant asso-
ciation between the serologic response and the interval
between bone marrow transplant (BMT) and vaccina-
tion. The second vaccine dose had only a marginal
effect. Pauksen et al. [23] found response rates in alloge-
neic SCT patients vaccinated 4 to 12 months after
HCT of 11/35 (31%) for H1N1, 3/35 (9%) for
H3N2, and 7/35 (20%) for influenza B. However, de-
spite suboptimal serologic responses, clinical effective-
ness of vaccination could potentially exist. Machado
et al. [24] found that influenza vaccination performed
at least 6 months after SCT had an efficacy in prevent-
ing influenza of 80%. It is possible that protection is
mediated also by T cells. Avetisyan et al. [25] analyzed
the T cell response in adult patients and found a signif-
icant increase in the number of IFN-g producing T
cells both in patients vaccinated between 3 and 6
months after HCT and in those vaccinated later, al-
though the response in the late group was stronger.
Furthermore, it has been shown in the elderly that the
risk for influenza disease is comparable in individuals
demonstrating a cell-mediated response alone, an anti-
body response alone, or both types of responses [26].
The response to vaccination is suboptimal early af-
ter transplantation also in autologousHSCT recipients
[22,23].No specific data exist regarding vaccine efficacy
in patients receiving rituximab in close proximity
to transplantation either during pretransplant
chemotherapy, as part of the conditioning regimen, or
after HSCT. However, in nontransplant patients the
immune response within 6 months of receiving
monoclonal antibodies is very poor [27], and it is there-
fore likely that this will be the case also after autologous
HSCT.
When the new pandemic H1N1 strain spread
rapidly around the world, new vaccines were rapidly
developed. There were uncertainties regarding effi-
cacy and safety of these vaccines, especially those in-
cluding new adjuvants. Preliminary data suggest that
2 doses of p/H1N1 vaccine were safe and able toinduce immune responses. In addition, the development
of antiviral resistance to neuraminidase inhibitors has
been demonstrated in immunocompromised hosts, al-
though no spreading of resistant virus was documented.
Life-long seasonal influenza vaccinationwith inacti-
vated influenza vaccine is recommended for all HSCT
recipients [28]. It is unknown how early vaccination
after HCT is beneficial. Because influenza vaccination
is safe, current recommendations are to start 4 months
after HSCT [28]. Influenza vaccination of family mem-
bers and household contacts is strongly recommended
during each influenza season to limit risks for influenza
exposure in HCT candidates or recipients. Seasonal
influenza vaccination is also strongly recommended
for health care workers dealing with HCT recipients.
Measles, mumps, and rubella (MMR) vaccine
Although severe and fatal measles has been
reported in HSCT recipients [29,30], the risk for
serious infection after allogeneic HSCT is likely to
be low. However, with more patients undergoing
transplantation after reduced intensity conditioning
(RIC) regimens, the pregnancy potential for patients
is likely to increase and thereby the risk of congenital
rubella syndrome. The available MMR vaccines are
live, attenuated vaccines, and are not recommended
for use in immunocompromised patients. Immuni-
zation can be considered in allogeneic HSCT
patients without chronic graft-versus-host disease
(cGVHD) or ongoing immunosuppression. Data indi-
cates that measles vaccine can be given to such patients
without severe adverse effects at 2 years after SCT [31].
During an epidemic in Brazil, patients were safely
immunized 1 year after SCT [32].
Varicella vaccines
Although data are limited, varicella vaccine might
be considered for seronegative HCT recipients who
meet the criteria for live virus vaccination delineated
above for measles vaccine. The zoster vaccine should
not be used. Two new inactivated varicella vaccines
are under development.
Other vaccines
There are no data regarding vaccination of HSCT
recipients with the recently licensed vaccines against
human papilloma virus, and vaccination cannot yet
be recommended. A new CMV vaccine is under devel-
opment, with phase II data showing promising immu-
nogenicity.
CONCLUSION
Viral infections in an immunocompromised host
have the ability to cause severe disease at much higher
rates than in the healthy population. Careful attention
to viral epidemiology and viral outbreaks in the
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tients with the onset of new respiratory symptoms,
and the use of careful infection control methods that
are rigorously enforced in both the outpatient and inpa-
tient setting are important in limiting viral spread to
these high risk patients. The use of antiviral therapy
prior to the development of respiratory failure may
also be of benefit in these patients. The efficacy of im-
munoglobulin products or monoclonal antibody prod-
ucts to limit the spread of infection within individual
patients is frequently utilized but has yet not been
proven in rigorous trials in this patient population. Fur-
ther clinical studies of agents to both prevent and treat
these important viral infections are urgently needed.
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